Financial news, markets, and business updates
An Indonesian court's decision against patent evergreening signals a shift towards improved medicine access, resonating with patient advocates globally.
Kyverna's recent study shows promising, enduring autoimmune relief from its cell therapy, signaling a significant advancement in treatment options.
The U.S. faces its most significant measles outbreak in over three decades, with unvaccinated individuals suffering the worst consequences.
Gilead Sciences is ramping up its commitment to inflammation and immunology, crucial for its future growth alongside virology and oncology.
Heidi Overton's ascent from a small New Mexico town to FDA commissioner nominee reflects her commitment to public health and leadership.
Radiology is evolving as practices actively adopt AI technologies to enhance services and attract talent, moving beyond fears of obsolescence.
Eli Lilly's latest breast cancer therapy has gained FDA approval, paving the way for enhanced treatment options in oncology.
Novo Nordisk outlines its strategy to broaden its pipeline, while Alkermes reveals hopeful ADHD treatment data, indicating potential new markets.
Alkermes' Phase 1 trial of ALKS 7290, designed for sleep disorders, indicates potential effectiveness for ADHD with significant symptom reduction.
Novo Nordisk aims to broaden its product pipeline beyond diabetes, targeting revenue growth with a focus on consumer-friendly approaches by 2030.
Pregnant and lactating individuals face barriers in finding relevant clinical trials due to a lack of structured data on their eligibility on ClinicalTrials.gov.
The FDA's approval of daraxonrasib provides new hope for pancreatic cancer patients, targeting the challenging KRAS mutation and improving survival rates significantly.
This article reflects on personal health struggles and the frustrations with today's medical system, highlighting a broader skepticism towards modern treatments.
Addiction clinics report a sharp rise in patients seeking help for kratom and 7-OH dependence amid growing warnings about these substances.
President Trump's recent announcement highlights efforts to reduce Medicaid drug prices, but many details remain unclear.
HCA Healthcare's Texas hospitals are suing Independence Blue Cross for $345,000 in claims, underlining persistent issues around prior authorization policies.
Recognizing the alcohol flush reaction is vital for East Asian communities; medical professionals play a key role in patient education about its risks.
A geriatrician emphasizes the need for caution in utilizing AI predictions for older patients, noting potential impacts on care decisions.
The FDA has approved Fayuvi, the first gene therapy for Sanfilippo syndrome, offering hope to affected families and changing treatment dynamics.
Pennsylvania's measles outbreak has claimed a fourth life, highlighting a growing public health crisis as vaccination rates decline.